Loading company
MDTMedtronic plc$131.6BA+Built from 20/20 Biolabs, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes 20/20 Biolabs is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$0.21+0.7%Nov 13 close
Reported results on November 13, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
Grade F
The band under the price shows the grade on each date, built only from filings that were public by then.
There is no grade history to chart for 20/20 Biolabs, Inc. yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.
